Myriad Genetics provides the following resources in select languages:

Revolutionary New Technology

Raise the bar for NIPS in your practice by virtually eliminating low fetal fraction samples.

EQUITY OF CARE FOR ALL PATIENTS

50% of pregnant patients present as high BMI to their OBGYN1. Many will be offered NIPS later in pregnancy or will be concerned about their result because of how a low fetal fraction may influence accuracy. This creates a disparity in care in pregnancy management.

Prequel™ with AMPLIFY™ technology raises NIPS performance most dramatically for the types of patients who have traditionally had low fetal fraction on standard NIPS due to high BMI or aneuploidy.

watch our recorded webinar

Learn more about Prequel with AMPLIFY Technology: the latest advancement in noninvasive prenatal screening (NIPS).

REVOLUTIONARY NEW TECHNOLOGY

3.9x amplification of fetal fraction in the traditionally difficult to call samples, originally coming in at below 4% fetal fraction.1

EVERYTHING JUST GOT BETTER

Now >99.9% of samples will present as >4% fetal fraction, with an industry leading test failure rate <0.1%.1 

ONE TEST FOR ALL PATIENTS

An equity of care across all patient populations.

NEW ACOG Practice Bulletin 226

States clearly that noninvasive prenatal screening is the most sensitive and specific screen.

Practice Bulletin 226 states:

“A low fetal fraction can cause cell-free DNA test failure… Accurate cell-free DNA screening requires a minimum fetal fraction, most commonly estimated at about 2–4%… In patients who weigh more than 250 pounds (113 kg), 10% may have a fetal fraction of less than 4%.” 

Cell-free DNA test failures are also seen more frequently in patients with high BMI, increasing maternal age, certain racial backgrounds (seen more frequently in Black women and South Asian women in comparison to white women).”2  

Partner in Patient Care

As your patients’ access to NIPS grows, the lab you choose becomes that much more important. Prequel with AMPLIFY is the only NIPS that virtually eliminates low fetal fraction samples in order to allow you to deliver equity in care across all patients, regardless of BMI, race, or ethnicity with a test failure rate of <0.1%.3 

DETERMINE INDIVIDUAL TWIN FETAL SEX WITH PREQUEL

AMPLIFY technology has not only enhanced the accuracy of NIPS across all measures, but it has also improved our ability to determine fetal sex and now, distinguish fetal sex in each individual twin, making us the only whole-genome sequencing-based NIPS lab to offer this and further strengthening our commitment to equity in care for ALL women. 

How is Myriad able to do this?

By evaluating the strength of the signal for chromosome Y we are able to distinguish between female/female, female/male, and male/male twin pregnancies. With an industry low test failure rate for singletons and twins at <0.1%2, you can feel confident in delivering accurate results the first time to ALL patients.

EVERYTHING JUST GOT BETTER WITH NIPS TECHNOLOGY

Learn more about Prequel with AMPLIFY technology.

Prequel with AMPLIFY Publication

Accepted in peer-reviewed journal: Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics

  1. Deputy, N.P., Dub, B. And Sharma, A. J. (2018). Prevalence and Trends in Prepregnancy Normal Weight – 48 States, New York City, and District of Columbia, 2011 – 2015, MMWR. Morbidity and morality weekly report, 66(51-52), pp. 1402-1407.
  2. ACOG Practice Bulletin #226: Screening for Fetal Chromosomal Abnormalities’ ‘Obstet Gynecol 2020;136.
  3. Hancock, et al. Clinical Experience for Noninvasive Prenatal Screen for Twins. NSGC 2020. 
  4. Welker et al., 2020. Under peer review (preprint at https://www.medrxiv.org/content/10.1101/2020.07.12.20034926v1).